Psomagen specializes in advanced genomic technologies that facilitate a wide range of applications in personalized medicine, drug development, and disease prevention. The company employs next-generation sequencing (NGS) techniques, which allow for rapid and accurate analysis of genetic material. This technology enables Psomagen to provide comprehensive genomic profiling, helping healthcare providers make informed decisions based on individual genetic information. Additionally, Psomagen utilizes bioinformatics tools to interpret complex genomic data, ensuring that clients receive actionable insights tailored to their specific needs.

In addition to NGS, Psomagen is involved in various other innovative technologies, including single-cell sequencing and metagenomics. Single-cell sequencing allows for the examination of individual cells, providing a deeper understanding of cellular diversity and function, which is crucial for cancer research and other complex diseases. Metagenomics, on the other hand, focuses on the genetic material recovered directly from environmental samples, enabling the study of microbial communities and their roles in health and disease. Together, these technologies position Psomagen at the forefront of genomic research and its applications in improving patient outcomes.

United States

Psomagen, Inc., formerly Macrogen Corp, delivers genomic sequencing services to the clinical, academic, and consumer markets. Psomagen's labs are US-based and CLIA and CAP certified. Not only is the company accredited to perform the highest quality Sanger sequencing, Next-Generation Sequencing and Microarray Gene Analysis, it is also networked with Macrogen's worldwide headquarters, stretching its capabilities and capacity across a diverse set of labs around the world. Learn more at psomagen.com.

Psomagen

Company Details